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Reply to the Editor:
Fundaro` and colleagues address the histor-
ically difficult task of creating a universally
accepted classification system for ischemic
mitral regurgitation (IMR). As they note,
multiple systems are used for the descrip-
tion of IMR. In fact, the three articles that
Fundaro` and coworkers cite,1-3 all of which
appeared in the same issue of the Journal,
contain slightly different categorizations
for IMR. The most important point, how-
ever, is that these three classification sys-
tems are actually quite similar to one an-
other. All are based on the mechanism(s) of
IMR.
Recent observations have furthered our
understanding of the pathophysiology of
IMR. In some instances, the mechanisms of
IMR are quite complicated; therefore,
some precision may be sacrificed as each
patient is placed in a single group that
specifies the predominant mechanism.
Nevertheless, such categorization will fa-
cilitate more meaningful communication of
the nature of IMR.
The authors of the three articles agree
that IMR may be caused by papillary mus-
cle disease or by changes in ventricular
and/or annular geometry, the latter result-
ing in functional IMR. Occasionally, more
than one of these mechanisms is operative.
Miller’s classification system1 is particu-
larly useful. He suggests that the primary
mechanism of IMR generally falls into one
of the following categories:
1. Papillary muscle rupture
2. Papillary muscle infarction and elon-
gation without rupture
3. Functional IMR from
a. Annular dilatation
b. Leaflet tethering
c. Annular dilatation and leaflet teth-
ering
By means of echocardiography, the major-
ity of patients with IMR can be placed into
one of these groups.
Fundaro` and colleagues offer a classifi-
cation system that is similar to the others
mentioned here. However, their distinction
between regional and global left ventricular
dysfunction does not speak directly to the
mechanism of IMR. Rather, it introduc-
esanother type of classification system. In
addition, subtype A (papillary muscle atro-
phy, elongation, or displacement) contains
disparate entities with different mecha-
nisms of IMR.
Classification systems have a long his-
tory of value in cardiac surgery and medi-
cine in general. They are designed to reflect
understanding of the nature of diseases (eg,
Miller’s classification of IMR), to facilitate
guidelines and indications for treatment
(eg, American Heart Association guide-
lines), to allow complex observations to be
communicated effectively (eg, nomencla-
ture for heart disease), and to reflect differ-
ences in prognosis (eg, cancer staging).
Fundaro`’s classification attempts to reflect
three different purposes of classification
systems simultaneously: mechanism, indi-
cations for operation, and prognosis. This
may be too ambitious, given the complex
nature of IMR.
We, Miller, and Grossi and colleagues
propose classification systems that address
clarity in understanding the mechanisms of
IMR. Choice of operation based on optimi-
zation of prognosis is a far more complex
and multifactorial issue that, at present, is
not clearly amenable to simple classifica-
tion.
Given our improved understanding of
the mechanisms of IMR, it is time that we
adopted a common classification system.
We recommend following Miller’s lead;
his mechanism-based description of IMR
permits clear categorization of patients.
A. Marc Gillinov, MD
Eugene H. Blackstone, MD
Department of Thoracic/Cardiovascular Surgery
The Cleveland Clinic Foundation
Desk F25
9500 Euclid Ave
Cleveland, OH 44195
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What are the best temperature, flow,
and hematocrit levels for pediatric
cardiopulmonary bypass?
To the Editor:
I read with great pleasure the letter by
Durandy, Hulin, and Lecompte1 on normo-
thermic cardiopulmonary bypass in pediat-
ric surgery, as well as the reply by Jonas,
Newburger, and Bellinger.2
I spent 1 year with Durandy and
Lecompte in Paris in 1995, at the beginning
of their experience with normothermic car-
diopulmonary bypass, and witnessed the
extremely smooth and “physiologic” post-
operative course of more than 300 consec-
utive children with congenital heart de-
fects. Most of them had very complicated
anatomy and intracardiac repair, and al-
most all of them were extubated very early,
without the need for inotropic support. I
repeatedly suggested that Durandy and
Lecompte report their extraordinary expe-
rience. Their reason for refusing to report
their data at that time was the need for
more substantial background.
I then decided to follow their methods
of cardiopulmonary bypass, and the initial
experience has been already reported.3,4
Therefore, I viewed the publication of their
letter with a great sense of relief, because
the feasibility and the advantages of nor-
mothermic cardiopulmonary bypass have
been now supported by their experience
with 1600 congenital cases.
To further support the message given in
the letter, I feel obliged to extend the in-
formation provided by Durandy, Hulin, and
Lecompte. In their letter they discussed
only the problem of temperature, although
there are at least other three factors used in
their practice of cardiopulmonary bypass
that contributed to their good results: flow,
hematocrit, and leukocyte depletion.
1. Flow. The flow generally used for
cardiopulmonary bypass is 2.0 to 2.4
L  m2  min1 or 100 to 120 mL 
kg1 min1. Even if this flow rate is
accepted as the gold standard for ad-
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equate systemic perfusion, and it is
called “full flow,” it is far from the
physiologic value of 3.5 to 5.0 L 
m2  min1. In most hospitals the
so-called “full flow” is reduced dur-
ing the central part of the procedure
to a low flow or to circulatory arrest.
The types of damage induced by
flow reduction (metabolic derange-
ment; endothelial lesions; vascular,
myocardial, neurologic, hemato-
logic, and respiratory impairment)
are not much different from those
induced by temperature reduction.3,4
In fact, I learned from the Paris
group to perfuse the children with a
flow of 3.0 to 3.5 L  m2  min1,
arbitrarily called “high flow.”
2. Hematocrit. The negative conse-
quences of a systemic perfusion with
low hematocrit, widely know for a
long time,3,4 are now acknowledged
even by Jonas. After years suggest-
ing that perfusion with high hemodi-
lution (hematocrit value around
20%) should be used, his group5 is
now providing evidence of better
neurologic protection with a hemat-
ocrit value of 30%. From the Paris
group I learned to maintain the he-
matocrit value at least at 30% during
cardiopulmonary bypass.
3. Leukocyte depletion. The role of
leukocyte activation as the main
cause of the postoperative inflamma-
tory syndrome, frequently observed
in the pediatric population, is gener-
ally well known, even if leukocyte
depletion is not yet used globally.
In summary, cardiopulmonary bypass as
used by the Paris group is not only normo-
thermic, but also associated with high flow,
high hematocrit, and leukocyte depletion.
In their reply to the letter, Jonas, New-
burger, and Bellinger2 suggested two main
objections: a small margin of safety in the
event of equipment failure and inadequate
surgical exposure.
1. Small margin of safety. The inci-
dence of “equipment failure” on car-
diopulmonary bypass reported in the
literature is between 1 every 1,000 or
10,000 procedures. Even if we con-
sider these figure as an underestima-
tion of the reality, this percentage is
much lower than the percentage of
children with low cardiac output,
need for extensive inotropic and re-
spiratory support, neurologic com-
plications, and the related mortality
and morbidity reported even in the
best centers after “conventional”
cardiopulmonary bypass.
2. Inadequate surgical exposure. The
good results of both the experience
of the Paris group1 with neonates
and infants with cyanotic congenital
heart defects (tetralogy of Fallot,
transposition of the great arteries)
and our more limited personal expe-
rience including infants with total
anomalous pulmonary venous con-
nection3,4 demonstrate the feasibility
of the technique. Of course, it is nec-
essary to have adequate venous
drainage, perfect surgical exposure,
and a surgeon ready to accept some
discomfort for himself (or herself)
rather than for the patients.
In conclusion, Durandy, Hulin, and
Lecompte are to be gratefully acknowl-
edged for teaching all of those involved in
the care of children with congenital heart
defects that surgery for congenital heart
disease can and should be performed with a
perfusion much closer to the physiologic
condition.
Antonio F. Corno, MD, FRCS, FETCS
Cardiovascular Surgery
Centre Hospitalier Universitaire Vaudois
(CHUV)
46 rue du Bugnon
CH-1011, Lausanne, Switzerland
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Reply to the Editor:
We thank Corno for his comments on our
recent letter. Obviously, normothermic car-
diopulmonary bypass associated with
warm blood cardioplegia is only part of the
perfusion protocol. The flow and the hemo-
globin level must be adapted to the sys-
temic oxygen consumption. The quality of
the donor blood product must be optimal,
but we must also stress the importance of a
low volume of priming fluid. We use 180
mL for neonates and infants with a body
surface area up to 0.27 m2 (4.5-5 kg) and
225 mL for infants up to 0.42 m2 (8-8.5
kg). We increase this volume progressively
to obtain a 600-mL prime volume for chil-
dren from 0.85 to 1.6 m2 (20-60 kg). With
this protocol we never use ultrafiltration
during or after bypass.
It is true that most of the surgeons who
visited us have been convinced by the ad-
vantages of this protocol and have changed
their minds about normothermic perfusion.
Several surgical units are now using this
method. We are reluctant to perform a pro-
spective randomized trial comparing hypo-
thermic and normothermic perfusion. We
hope that, in the not too distant future, we
will have enough data to publish a single-
center or a multicenter experience about
normothermic cardiopulmonary bypass in
pediatric surgery.
Yves Durandy, MD
Sylvie Hulin, MD
Yves Lecompte, MD
ICPS—Institut Jacques Cartier
Avenue du Noyer Lambert
Massy, France
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